The mechanism of action of BCG therapy for bladder cancer--a current perspective. - Wikidata - awgldk - TriplyDB

The mechanism of action of BCG therapy for bladder cancer--a current perspective.

The mechanism of action of BCG therapy for bladder cancer--a current perspective.

http://www.wikidata.org/entity/Q38184849

about

Immunobiology and immunotherapy in genitourinary malignancies Inhibiting Immune Checkpoints for the Treatment of Bladder Cancer Bacteria in Cancer Therapy: Renaissance of an Old Concept The role of mycobacterial cell wall nucleic acid complex in the treatment of bacillus Calmette-Guérin failures for non-muscle-invasive bladder cancer Bladder Cancer Stem-Like Cells: Their Origin and Therapeutic Perspectives Managing the adverse events of intravesical bacillus Calmette-Guérin therapy Management of carcinoma in situ of the bladder: best practice and recent developments Immunostimulatory Gene Therapy Using Oncolytic Viruses as Vehicles Targeting Hsp90 in urothelial carcinoma Mycobacteria emulsified in olive oil-in-water trigger a robust immune response in bladder cancer treatment.Prediction of Bacillus Calmette-Guerin Response in Patients with Bladder Cancer after Transurethral Resection of Bladder Tumor by Using Genetic Variation Based on Genomic Studies The Role of Toll-Like Receptors in Hematopoietic Malignancies EZH2 in Bladder Cancer, a Promising Therapeutic Target Deletion of F4L (ribonucleotide reductase) in vaccinia virus produces a selective oncolytic virus and promotes anti-tumor immunity with superior safety in bladder cancer models.Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges.Cancer and the microbiota.Immunotherapy for bladder cancer.Systemic therapy for bladder cancer - a medical oncologist's perspective.Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.Inoculation site from a cutaneous melanoma patient treated with an allogeneic therapeutic vaccine: a case report.Modelling bladder cancer in mice: opportunities and challenges.Mincle, an Innate Immune Receptor, Is Expressed in Urothelial Cancer Cells of Papillomavirus-Associated Urothelial Tumors of Cattle.The interplay of extracellular matrix and microbiome in urothelial bladder cancer.Manipulation of BCG vaccine: a double-edged sword.Microbiome, a new dimension in cancer research Differential Adverse Event Profiles Associated with BCG as a Preventive Tuberculosis Vaccine or Therapeutic Bladder Cancer Vaccine Identified by Comparative Ontology-Based VAERS and Literature Meta-Analysis High CD4⁺ T cell density is associated with poor prognosis in patients with non-muscle-invasive bladder cancer High CD204+ tumor-infiltrating macrophage density predicts a poor prognosis in patients with urothelial cell carcinoma of the bladder.Mutated Fanconi anemia pathway in non-Fanconi anemia cancers Englerin A induces an acute inflammatory response and reveals lipid metabolism and ER stress as targetable vulnerabilities in renal cell carcinoma Pharmacogenomics: Biomarker-Directed Therapy for Bladder Cancer.Transient microbiota exposures activate dormant Escherichia coli infection in the bladder and drive severe outcomes of recurrent disease.Antiandrogen Therapy with Hydroxyflutamide or Androgen Receptor Degradation Enhancer ASC-J9 Enhances BCG Efficacy to Better Suppress Bladder Cancer Progression.Pathogen boosted adoptive cell transfer immunotherapy to treat solid tumors.Questions and challenges associated with studying the microbiome of the urinary tract.Spotlight on atezolizumab and its potential in the treatment of advanced urothelial bladder cancer.Insights into Local Tumor Microenvironment Immune Factors Associated with Regression of Cutaneous Melanoma Metastases by Mycobacterium bovis Bacille Calmette-Guérin.Cytokines as effectors and predictors of responses in the treatment of bladder cancer by bacillus Calmette-Guérin.Recombinant bacillus Calmette-Guérin in urothelial bladder cancer immunotherapy: current strategies.Immune therapies in non-muscle invasive bladder cancer.

P2860

Q26738668-864B1751-19F7-4D56-9720-790FB72C8B45 Q26744758-E6CE3226-E82E-45F1-AA90-6C605107BD4B Q26751222-D68C33C3-FB88-49C7-BF04-13300D312B26 Q26770422-87FD61DF-4E18-4E79-B0DD-A9055D36ED24 Q26771263-E978D7E1-8DC6-433F-8EDE-D114EBBF90EC Q26775644-0D0DBC4F-7350-485C-92B8-BBAACF15DB75 Q26775772-148C722E-B328-4C83-9287-97825E9E52D5 Q26777403-7F29C3EC-E548-4823-B98B-6009F50B84E1 Q27023406-24227726-30BB-469C-9D6F-58B9EDC05170 Q27346705-0C1D270E-0122-466A-B009-FD6B15738A2A Q28076563-08EFFE9A-E18D-4F77-B1AA-9E8DF7CCD2FB Q28077740-C50ACE34-85AB-4AAD-B407-3E3B53B5373A Q28082054-918E39C8-0D05-4382-953F-FE7037A7BDCF Q33625843-F3633E64-C043-48C2-8F69-A5356CB60A13 Q34439339-ED6705C1-7922-40EF-B884-3BCDD1EF7BCE Q34470083-8BDDD4C9-2C06-4659-B783-7930C5464EA4 Q34477444-7E53216D-F919-4651-A13C-96186D6A7CB0 Q34516731-95187C82-BC6C-4F9D-8096-DCAF108B4A2A Q34545316-25FA6A24-5597-4244-A342-289C982A5C95 Q35229087-8F72C749-69F1-4C56-AC84-5015EDAAF3D0 Q35285703-71E48720-24A2-4DC8-8185-8BD0937BA613 Q35826351-69331783-7F76-44D7-B080-85B1A75D9357 Q35868405-C102C073-536A-47FA-8F1D-9C7A491C0826 Q35904315-799AE878-47FB-441E-B580-0172D10E88C8 Q36138105-0CE9B576-99C6-418F-8CB6-812C5657983D Q36165332-BDA4E9FE-8B45-4A79-9768-BBC1A799B623 Q36261897-FB3FF637-4554-4411-B19C-3F1D9FD38897 Q36299634-13A38821-6E49-467F-9940-72A6C5A290C9 Q36299696-57D410F6-AE76-479B-986E-D5116F6F599A Q36308931-32EE2B6F-401B-455C-B0E3-6014BAC57971 Q36328010-C67DF51B-2ABC-462A-9233-E7986A5F37BE Q36328388-8BF4CEF9-87A1-44E2-A534-E39BC7B4DEDC Q36439816-F7114B10-611F-4F8C-B794-284D7D31421C Q37612527-78FB46F7-CDF1-4406-8D00-CD78FDAC5A44 Q37634443-FDD1DBA5-CD4A-4249-9F05-5E02BD1BEBC4 Q37702430-7E740AC9-E0D7-40B5-B1F0-9529D4900B1C Q37737540-CCD8AE84-3A32-41DE-87BC-9783CBA5E7E2 Q38232854-0E867F13-8548-49EC-BC36-93474ECF58A9 Q38251141-9593E258-95E8-4C1E-8530-EC4F4DBB9FFD Q38372571-FF922BE1-1745-40FF-AEBC-7AA5F3194630

P2860

The mechanism of action of BCG therapy for bladder cancer--a current perspective.

http://www.wikidata.org/entity/Q38184849

description

article científic

@ca

article scientifique

@fr

articol științific

@ro

articolo scientifico

@it

artigo científico

@gl

artigo científico

@pt

artigo científico

@pt-br

artikel ilmiah

@id

artikull shkencor

@sq

artículo científico

@es

name

The mechanism of action of BCG therapy for bladder cancer--a current perspective.

@en

type

label

The mechanism of action of BCG therapy for bladder cancer--a current perspective.

@en

prefLabel

The mechanism of action of BCG therapy for bladder cancer--a current perspective.

@en

P1433

Q38184849-34896BA6-5FDF-4ADB-B83A-9AA0BCD63E22

P1476

Q38184849-69FFF007-5CB6-4AE6-85FE-C73D97A00DF5

P2093

Q38184849-4ED3F9D7-1F9C-4D49-B024-F05624B74698

Q38184849-CA36B977-587D-4C3A-A72A-591EB208847F

P2860

Q38184849-05AB0EA0-707D-4262-8831-3BBD1FF2C776

Q38184849-0639B15A-1793-4678-9C43-E108B0BBF239

Q38184849-08B09E97-E032-4F11-8530-F161CC1929DC

Q38184849-1CEF253F-89AC-4915-8B7B-503CE8A7CA1C

Q38184849-1E1245E4-78B4-4B74-AE4A-226F13527AC8

Q38184849-22C23F1E-C1CE-424E-829F-D6DAFF2677A1

Q38184849-246465DE-E4F8-42AA-85BE-A8E799807C87

Q38184849-345D829E-FD9B-455C-A8EE-7DD99059EFC9

Q38184849-48733073-FF13-4B41-BF4F-FB30AB0BFB4B

Q38184849-4D1DD57B-8773-4E64-AAB9-1C816DE5D28E

P2888

Q38184849-B6F74BFA-4BFB-4D59-8A2B-C077DA7FD72C

P304

Q38184849-7432C0DF-F9DD-4F1B-8423-B114D0094AFF

P31

Q38184849-33217C38-68B8-42FE-B93F-80967E4C3005

P356

Q38184849-280DDADA-80B8-445E-B20C-89517D791A79

P407

Q38184849-DCBDD543-2972-4CFF-B84C-0AAC0BA8F345

P433

Q38184849-D42DEE61-DB3D-490F-9A2F-D8B51BE103E5

P478

Q38184849-E0D53792-ADD2-41B5-BF33-D3AC6466EB9C

P50

Q38184849-91C3726C-5113-4D6C-8B5F-A67AF019E8D5

P577

Q38184849-97080E05-A11A-49F4-B9E9-5F900DF69F3C

P6179

Q38184849-52BC156D-00A5-4FCA-B579-4611EF962861

P698

Q38184849-F4DCEA29-6E4D-4CF0-B1F6-B83C254C568E

P356

P1433

Nature Reviews Urology

P1476

The mechanism of action of BCG therapy for bladder cancer--a current perspective.

@en

P2093

Gil Redelman-Sidi

http://www.w3.org/2001/XMLSchema#string

Michael S Glickman

http://www.w3.org/2001/XMLSchema#string

P2860

An endotoxin-induced serum factor that causes necrosis of tumors

BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking.

A systematic review of intravesical bacillus Calmette-Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer.

Macrophages are a significant source of type 1 cytokines during mycobacterial infection.

Fibronectin-mediated Calmette-Guerin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response

TRAIL and apoptosis induction by TNF-family death receptors.

Intravesical bacillus Calmette-Guérin is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.

Identification of the mycobacterial subcomponents involved in the release of tumor necrosis factor-related apoptosis-inducing ligand from human neutrophils

Characterization of the internalization of bacillus Calmette-Guerin by human bladder tumor cells.

Inhibition of mycobacterial infection by the tumor suppressor PTEN.

P2888

P304

153-162

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/NRUROL.2014.15

http://www.w3.org/2001/XMLSchema#string

P407

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

11

http://www.w3.org/2001/XMLSchema#string

P50

Bernard H Bochner

P577

2014-02-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1002890025

http://www.w3.org/2001/XMLSchema#string

P698

24492433

http://www.w3.org/2001/XMLSchema#string